Lexicon Pharmaceuticals Inc
NASDAQ: LXRX
$0.86
+$0.09 (+11.9%)
Closing Price on November 22, 2024
LXRX Articles
These top picks from Wedbush offer varying degrees of risk and upside. The fact that they are not crowded momentum plays makes them far more attractive for the rest of 2017 and into next year.
Published:
Last Updated:
Equifax, New York REIT, Opko, and Lexicon Pharma all posted new 52-week lows Thursday.
Published:
Last Updated:
Hewlett Packard Enterprise, Equifax, New York REIT, and Lexicon Pharmaceuticals all posted new 52-week lows on Wednesday.
Published:
Last Updated:
The top analyst upgrades, downgrades and other research calls from Monday Adobe, Alibaba, Apple, Pandora, Vodafone, Cigna and Lexicon Pharma.
Published:
Last Updated:
Shares of Lexicon Pharmaceuticals saw a hand gain early on Friday after the company reported top-line results from its late-stage trial in type-1 diabetes.
Published:
Last Updated:
Here are three biotech companies that not only have data that could prove to be huge, but their shares have been absolutely hammered over the last year, offering aggressive accounts the best entry...
Published:
Last Updated:
Wednesday’s top analyst upgrades, downgrades and initiations include Abbott Labs, General Dynamics, Nexstar Media, Owens Corning, Palo Alto Networks and Salesforce.com.
Published:
Last Updated:
Wedbush has issued a report with some of its best ideas for 2016. These top six ideas from this list have implied upside of at least 50%.
Published:
Last Updated:
Some biopharma companies can see a massive upside just from winning a single mid-stage trial or even achieving as much as a Fast Track designation from the FDA.
Published:
Last Updated:
24/7 Wall St. has collected several catalysts for biotech and pharmaceutical companies that are coming up in the first two months of 2017.
Published:
Last Updated:
24/7 Wall St. has collected several catalysts that are coming up on the calendar in the month of December.
Published:
Last Updated:
Some biotech companies made impressive runs over the course of this past week. These select few stood out from the rest.
Published:
Last Updated:
Lexicon Pharmaceuticals rallied Friday on late-stage results from a pivotal Phase 3 clinical trial of a type 1 diabetes treatment.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and added some color.
Published:
This past week was a break from the endless, six-year bull market. Still, the market remains effectively at all-time highs.
Published:
Last Updated: